CoChat

LONG-TERM RESULTS OF INTRAVITREAL RANIBIZUMAB, INTRAVITREAL RANIBIZUMAB WITH PHOTODYNAMIC THERAPY, AND INTRAVITREAL TRIAMCINOLONE WITH PHOTODYNAMIC THERAPY FOR THE TREATMENT OF RETINAL ANGIOMATOUS PROLIFERATION

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

In Brief Purpose: To compare intravitreal ranibizumab, intravitreal ranibizumab plus photodynamic therapy (PDT), and intravitreal triamcinolone plus PDT in retinal angiomatous proliferation, presenting the results of a 3-year follow-up. Methods: Thirty-seven eyes of 37 patients with retinal angiomatous proliferation were randomized to 1 of the 3 groups. Group 1 (n = 13) received 3 monthly injections of 0.5 mg ranibizumab, Group 2 (n = 13) received 1 session of PDT and 3 monthly injections of ranibizumab, and Group 3 (n = 11) received 1 session of PDT and 1 injection of 4 mg triamcinolone. Retreatment, with the same therapeutic scheme in each group, was considered in case of persistence or recurrence of subretinal/intraretinal fluid. Results: Twelve patients in Groups 1 and 2 and 9 patients in Group 3 completed the 3-year follow-up. A total of 58% of patients in Group 1, 50% in Group 2, and 88.9% in Group 3 had the same or better visual acuity at the end of the follow-up (P = 0.081). Patients in Group 3 exhibited considerable improvement in visual acuity (P = 0.032) and statistically significant decrease in central retinal thickness (P < 0.0001) than the 2 other groups at the end of the follow-up. Also, the patients in Group 3 received on average the lowest number of injections (P < 0.0001). Of note, geographic atrophy mainly at the place of previous retinal angiomatous proliferation lesion was detected in 0% in Group 1, 25% in Group 2, and 55.6% in Group 3 (P = 0.203), while 33.3% of patients in Group 1 developed retinal scar. Conclusion: Treatment with ranibizumab or ranibizumab plus PDT resulted in stabilization of the disease, while treatment with IVT plus PDT achieved better results in terms of functional and anatomical features compared with the other groups. Our study compares three therapeutic modalities against retinal angiomatous proliferation. Treatment with ranibizumab or ranibizumab plus photodynamic therapy resulted in stabilization of the disease, while treatment with intravitreal triamcinolone plus photodynamic therapy achieved better results in terms of functional and anatomical features compared with the other groups.

Overview

Integrity signals

Registry

Crossref · 10.1097/iae.0b013e318235d8ce

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Cited by

Metadata

Authors
Rouvas, A. A., Chatziralli, I. P., Theodossiadis, P. G., Moschos, M. M., Kotsolis, A. I., & Ladas, I. D.
Affiliations
National and Kapodistrian University of Athens (GR)
Corresponding author
  • Rouvas, Alexandros A.
  • Theodossiadis, Panagiotis G.
Venue
Retina
Published
2012-06
Volume
32
Issue
6
Pages
1181-1189
ISSN
0275-004X (ISSN-L)
OpenAlex
W2074013967
Cited by
30
References
45
Citations by year
2026: 1 · 2025: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 5 · 2016: 4 · 2015: 4 · 2014: 4 · 2013: 4
FWCI
3.60
Type
journal article
Language
en
Open access
closed
Locations
  • Retina (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
ranibizumab, photodynamic therapy, intravitreal triamcinolone acetonide, retinal angiomatous proliferation, geographic atrophy, retinal scarring, visual acuity, central retinal thickness, anti-VEGF therapy, long-term outcomes, subretinal fluid, intraretinal fluid, retreatment, anti-inflammatory therapy, anti-angiogenic therapy, choroidal neovascularization
MeSH terms
Ranibizumab, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Photochemotherapy, Triamcinolone, Visual Acuity, Retinal Neovascularization, Angiogenesis Inhibitors, Intravitreal Injections, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.